Kui Young Park
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Kui Young Park has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
Beom Joon Kim
Department of Dermatology, Chung-Ang University College of Medicine, Seoul, Korea
3 shared publicationsSang Ju Lee
Yonsei Star Skin & Laser Clinic, Seoul, South Korea
3 shared publications- Beom Joon Kim
Ulsan University Hospital, University of Ulsan College of Medicine
2 shared publications Joon Seok
Department of Dermatology, Chung-Ang University College of Medicine, Seoul, Korea
2 shared publicationsMyeung Nam Kim
Department of Dermatology, Chung-Ang University College of Medicine, Seoul, Korea
2 shared publications- Adam B. Johnson
University of Arkansas for Medical Sciences
1 shared publication
Latest Publications
- 12 April 2019
- Published by Wiley in Dermatologic Therapy
- Vol. 32 (4) , e12922
Case series of post‐purpuric darkness on the periorbital area after aesthetic surgery
Periorbital hyperpigmentation (POH) is a common condition encountered in dermatology practice. POH is caused by various exogenous and endogenous factors including excessive pigmentation, post‐inflammatory hyperpigmentation (PIH) secondary to eczema, periorbital edema, excessive vascularity, and aging. (Freitag & Cestari, 2007; Roh & Chung, 2009; Sarkar et al., 2016) Recently, we have experienced several patients who complained of POH with an unusual pattern. Their pigmented lesions had several features in common. The pigmentation occurred bilaterally after aesthetic surgery involving the periorbital region. Periorbital post‐purpuric darkness should be distinguished from common POH. Practitioners should ask patients about history of prior aesthetic surgery and make their patients aware that the dark colors are composed of various pigments such as hemosiderin, which make treatment troublesome. Conservative management with expectations for gradual spontaneous regression or laser therapy with multiple wavelengths including 1064‐nm laser for PIH and 650 or 694‐nm laser targeting heme‐derived pigments may be considered as treatment options.
- 12 April 2019
- Published by Wiley in Dermatologic Therapy
- Vol. 32 (4) , e12922
Case series of post‐purpuric darkness on the periorbital area after aesthetic surgery
Periorbital hyperpigmentation (POH) is a common condition encountered in dermatology practice. POH is caused by various exogenous and endogenous factors including excessive pigmentation, post‐inflammatory hyperpigmentation (PIH) secondary to eczema, periorbital edema, excessive vascularity, and aging. (Freitag & Cestari, 2007; Roh & Chung, 2009; Sarkar et al., 2016) Recently, we have experienced several patients who complained of POH with an unusual pattern. Their pigmented lesions had several features in common. The pigmentation occurred bilaterally after aesthetic surgery involving the periorbital region. Periorbital post‐purpuric darkness should be distinguished from common POH. Practitioners should ask patients about history of prior aesthetic surgery and make their patients aware that the dark colors are composed of various pigments such as hemosiderin, which make treatment troublesome. Conservative management with expectations for gradual spontaneous regression or laser therapy with multiple wavelengths including 1064‐nm laser for PIH and 650 or 694‐nm laser targeting heme‐derived pigments may be considered as treatment options.
- 5 September 2018
- Published by Taylor & Francis in Journal of Cosmetic and Laser Therapy
- Vol. 21 (4) , 225-227
Topical brimonidine-assisted laser treatment for the prevention of therapy-related erythema and hyperpigmentation
Postinflammatory hyperpigmentation (PIH) and erythema are the most common adverse effects associated with laser treatment, particularly in dark-skinned individuals. Several methods have been used to prevent or minimize these adverse effects; however, to date, no definitive precautions/strategies are known to prevent post-laser PIH and erythema. We investigated whether the topical application of the α-adrenergic receptor agonist brimonidine could reduce laser treatment-related complications such as erythema and PIH.
- 5 September 2018
- Published by Taylor & Francis in Journal of Cosmetic and Laser Therapy
- Vol. 21 (4) , 225-227
Topical brimonidine-assisted laser treatment for the prevention of therapy-related erythema and hyperpigmentation
Postinflammatory hyperpigmentation (PIH) and erythema are the most common adverse effects associated with laser treatment, particularly in dark-skinned individuals. Several methods have been used to prevent or minimize these adverse effects; however, to date, no definitive precautions/strategies are known to prevent post-laser PIH and erythema. We investigated whether the topical application of the α-adrenergic receptor agonist brimonidine could reduce laser treatment-related complications such as erythema and PIH.
- Open Access
- 1 February 2018
- Published by Korean Dermatological Association and The Korean Society for Investigative Dermatology in Annals of Dermatology
- Vol. 30 (1) , 102-104
Investigating Skin Penetration Following Needle-Free Injection Combined with Fractional Laser and Subcision
Seok J, et al. Ann Dermatol. 2018 Feb;30(1):102-104. https://doi.org/10.5021/ad.2018.30.1.102
- 1 February 2018
- Published by Korean Dermatological Association and The Korean Society for Investigative Dermatology in Annals of Dermatology
- Vol. 30 (1) , 102-104
Open AccessInvestigating Skin Penetration Following Needle-Free Injection Combined with Fractional Laser and Subcision
Seok J, et al. Ann Dermatol. 2018 Feb;30(1):102-104. https://doi.org/10.5021/ad.2018.30.1.102
- 1 January 2018
- Published by Wiley in Clinical and Experimental Dermatology
- Vol. 43 (1) , 62-63
Allergic contact dermatitis caused by a moisturizer containing iodopropynyl butylcarbamate
- 1 January 2018
- Published by Wiley in Clinical and Experimental Dermatology
- Vol. 43 (1) , 62-63
Allergic contact dermatitis caused by a moisturizer containing iodopropynyl butylcarbamate
- 1 July 2017
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 77 (1) , e5-e6
Reduction of early nodules after injection of hyaluronic acid filler
- 1 July 2017
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 77 (1) , e5-e6
Reduction of early nodules after injection of hyaluronic acid filler
- Open Access
- 1 January 2017
- Published by Korean Dermatological Association and The Korean Society for Investigative Dermatology in Annals of Dermatology
- Vol. 29 (6) , 820-821
Inverse Psoriasis with Autoimmune Hepatitis
- 1 January 2017
- Published by Korean Dermatological Association and The Korean Society for Investigative Dermatology in Annals of Dermatology
- Vol. 29 (6) , 820-821
Open AccessInverse Psoriasis with Autoimmune Hepatitis
- Open Access
- 22 September 2014
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 15 (9) , 16800-16815
Mycophenolate Antagonizes IFN-γ-Induced Catagen-Like Changes via β-Catenin Activation in Human Dermal Papilla Cells and Hair Follicles
Recently, various immunosuppressant drugs have been shown to induce hair growth in normal hair as well as in alopecia areata and androgenic alopecia; however, the responsible mechanism has not yet been fully elucidated. In this study, we investigate the influence of mycophenolate (MPA), an immunosuppressant, on the proliferation of human dermal papilla cells (hDPCs) and on the growth of human hair follicles following catagen induction with interferon (IFN)-γ. IFN-γ was found to reduce β-catenin, an activator of hair follicle growth, and activate glycogen synthase kinase (GSK)-3β, and enhance expression of the Wnt inhibitor DKK-1 and catagen inducer transforming growth factor (TGF)-β2. IFN-γ inhibited expression of ALP and other dermal papillar cells (DPCs) markers such as Axin2, IGF-1, and FGF 7 and 10. MPA increased β-catenin in IFN-γ-treated hDPCs leading to its nuclear accumulation via inhibition of GSK3β and reduction of DKK-1. Furthermore, MPA significantly increased expression of ALP and other DPC marker genes but inhibited expression of TGF-β2. Therefore, we demonstrate for the first time that IFN-γ induces catagen-like changes in hDPCs and in hair follicles via inhibition of Wnt/β-catenin signaling, and that MPA stabilizes β-catenin by inhibiting GSK3β leading to increased β-catenin target gene and DP signature gene expression, which may, in part, counteract IFN-γ-induced catagen in hDPCs.
- 22 September 2014
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 15 (9) , 16800-16815
Open AccessMycophenolate Antagonizes IFN-γ-Induced Catagen-Like Changes via β-Catenin Activation in Human Dermal Papilla Cells and Hair Follicles
Recently, various immunosuppressant drugs have been shown to induce hair growth in normal hair as well as in alopecia areata and androgenic alopecia; however, the responsible mechanism has not yet been fully elucidated. In this study, we investigate the influence of mycophenolate (MPA), an immunosuppressant, on the proliferation of human dermal papilla cells (hDPCs) and on the growth of human hair follicles following catagen induction with interferon (IFN)-γ. IFN-γ was found to reduce β-catenin, an activator of hair follicle growth, and activate glycogen synthase kinase (GSK)-3β, and enhance expression of the Wnt inhibitor DKK-1 and catagen inducer transforming growth factor (TGF)-β2. IFN-γ inhibited expression of ALP and other dermal papillar cells (DPCs) markers such as Axin2, IGF-1, and FGF 7 and 10. MPA increased β-catenin in IFN-γ-treated hDPCs leading to its nuclear accumulation via inhibition of GSK3β and reduction of DKK-1. Furthermore, MPA significantly increased expression of ALP and other DPC marker genes but inhibited expression of TGF-β2. Therefore, we demonstrate for the first time that IFN-γ induces catagen-like changes in hDPCs and in hair follicles via inhibition of Wnt/β-catenin signaling, and that MPA stabilizes β-catenin by inhibiting GSK3β leading to increased β-catenin target gene and DP signature gene expression, which may, in part, counteract IFN-γ-induced catagen in hDPCs.